APRIL (AbatacePt in Rheumatoid Arthritis-ILD)

Rheumatoid Arthritis Clinical Trial

— APRIL  

Official title:

Safety of Abatacept in Rheumatoid Arthritis Associated Interstitial Lung Disease: A Feasibility Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03084419
• Other study ID #: APRIL
• Status: Recruiting
• Phase: Phase 2
• Start date: June 26, 2018
• Est. completion date: March 1, 2020

Study information

• Verified date: July 2019
• Source: Cambridge University Hospitals NHS Foundation Trust
• Contact: Frances Hall
• Phone: 01223 274915
• Email: frances.hall[@]addenbrookes.nhs.uk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Early initiation of treatment for Rheumatoid arthritis (RA) can prevent several of the long term problems associated with the condition. However, many RA patients develop lung inflammation and scarring, called 'interstitial lung disease' (RA-ILD), contributing to early death in 1 in 5 people. There is no proven treatment for these patients and some medications for RA can in fact worsen their lung disease. There is a need therefore to find safe medications that can not only control RA joint disease, but also prevent progression of RA-ILD. Abatacept is an approved drug for treating RA and is used widely. It is a newer RA medication, with a unique mechanism of action, and it has been shown to prevent progression of joint damage and improve physical function. The investigators aim to assess the safety of this medication in patients with RA-ILD and improve our understanding of the mechanism of lung damage in rheumatoid disease.

The investigators will perform a small clinical trial to assess the feasibility of performing a larger randomized controlled trial. A total of 30 patients with RA-ILD will be treated with abatacept infusions fortnightly for the first month, then every 4 weeks for a total of 20 weeks. In order to be eligible for the study, a patient must be able to provide written informed consent, be aged ≥18 years, and have interstitial lung disease that has not responded to or progressed over 6 months despite conventional immunosuppression. Change in lung function (forced vital capacity) at 24 weeks will be evaluated. To assess the mechanisms that may be involved with the development of ILD, the investigators will assess the effects of abatacept on biomarkers obtained from the blood and the lung (bronchoalveolar lavage), including markers of infection (the lung microbiome).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: March 1, 2020
• Est. primary completion date: March 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Aged 18 years or over

• Agree to use 2 acceptable forms of effective contraception for the duration of the study trial and a further 14 weeks after completion

• Meet a diagnosis of RA by 2010 EULAR/ACR criteria

• Have interstitial lung disease associated with RA, with supportive findings on their PFTs and CT Chest scans. Participants will be included if their ILD has progressed over 14 months. Progression will be defined as EITHER:

• A decrease in FVC by at least 5% when comparing two sets of PFTs done in the last 24 months, but with an interval of up to 14 months between the PFTs OR

• Progression of lung fibrosis on a high-resolution CT chest, as reported by a chest radiologist.

Exclusion Criteria:

• Unable to provide informed written consent

• Participants who are taking other immunosuppressants, e.g. mycophenolate mofetil (MMF), unless this has been discontinued with an adequate washout period. The exceptions to this exclusion criterion are methotrexate (MTX) and hydroxychloroquine, which are allowed provided the dose has been stable for 6 weeks prior to baseline (visit 2).

• Participants who have been taking > 10mg Prednisolone daily within the last 6 weeks prior to baseline (visit 2)

• Participants who have had rituximab, within the 24 weeks prior to baseline (Visit 2)

• Any participant with active signs or symptoms of infection at the baseline (visit 2) or requiring antibiotic treatment within the preceding 4 weeks

• Any participant with significant co-existing lung disease, such as asthma, bronchiectasis, emphysema, Chronic Obstructive Pulmonary Disease (COPD) or if their pre-bronchodilator FEV1/FVC ratio is < 60%.

• Significant other co-morbidity (e.g. active malignancy/liver disease/renal disease) within the last 5 years

• Prior use of abatacept at any time

• Participation in any other clinical trial within 8 weeks or 5 half-lives of IMP, whichever is longer, prior to baseline (visit 2) (participation in 'observational' studies is allowed)

• Hypersensitivity to any excipients of abatacept

• Any participant who has had live vaccines within 6 weeks prior to baseline (Visit 2)

• Participant is pregnant or breastfeeding

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Interstitial Lung Disease
• Lung Diseases
• Lung Diseases, Interstitial
• Rheumatoid Arthritis

Intervention

Drug:
• Abatacept
The IV dose varies according to weight: <60kg=500mg =60 but=100kg=750mg >100kg=1g This equates to approximately 10mg/kg.

Locations

Country	Name	City	State
United Kingdom	Addenbrookes Hospital	Cambridge
United Kingdom	Papworth Hospital	Cambridge

Sponsors (2)

Lead Sponsor	Collaborator
Cambridge University Hospitals NHS Foundation Trust	Bristol-Myers Squibb

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Forced Vital Capacity (FVC)	Assessing the change of Forced Vital Capacity (FVC) across screening, baseline V2 (prior to abatacept), V6 and V9.	28 weeks (Screening-V9)
Secondary	Transfer factor of the lung for carbon monoxide (TLCO)	Assessing the change of Transfer factor of the lung for carbon monoxide (TLCO) at screening (prior to abatacept), V6 and V9.	28 weeks (Screening-V9)
Secondary	MRC dyspnoea score	Assessing the change of MRC dyspnoea score completed at Baseline V2 (prior to abatacept), V6, V9	24 weeks (Baseline-V9)
Secondary	Kings Brief Interstitial Lung Disease score (K-BILD)	Assessing the change of Kings Brief Interstitial Lung Disease score (K-BILD) questionnaire completed at Baseline V2 (prior to abatacept), V6, V9	24 weeks (Baseline-V9)
Secondary	Semi-quantitative radiological scoring of the ILD	Assessing the change of HRCT chest scans performed at screening (prior to abatacept and V9 (end of trial)	28 weeks (Screening-V9)
Secondary	Resting oxygen saturation	Resting oxygen saturation recorded at all visits	28 weeks
Secondary	DAS28	DAS28 recorded at all visits	28 weeks
Secondary	Leicester Cough Questionnaire score	Assessing the change of Leicester Cough Questionnaire completed at Baseline V2 (prior to abatacept), V6, V9	24 weeks (Baseline-V9)
Secondary	EQ-5D	Assessing the change of EQ-5D Questionnaire completed at Baseline V2 (prior to abatacept), V6, V9	24 weeks (Baseline-V9)
Secondary	Respiratory tract infection	Assessing the number of Respiratory tract infections recorded following IMP dosing between V2-V9	24 weeks (Baseline-V9)